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Is Next Twelve Months Period Tumor Recurrence Free Under Restricted Rate 
Due to Medication? A Probabilistic Warning 
 
Ramalingam Shanmugam 
Texas State University, 
San Marcos, TX USA 
 
 
A methodology is formulated to analyze tumor recurrence data when its incidence rate is restricted due to 
medication. Analytic results are derived to make a probabilistic early warning of tumor recurrence free 
period of length τ; that is, the chance for a safe period of lengthτ is estimated. The captured data are 
length biased. Expressions are developed to extract and relate to counterparts of the non-length biased 
data. Three data sets are considered as illustrations: (1) patients who are given a placebo, (2) patients who 
are given the medicine pyridoxine and (3) patients who are given the medicine thiotepa. 
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Introduction 
Cancer is the second major cause of death after 
cardiovascular deaths in USA. Tumor, an 
abnormal growing of cells in the brain, is an 
important category in the cancer group and 
remains mysterious to medical researchers. 
Whether a tumor is a benign or malignant type, 
its recurrence time must be speculated for an 
efficient treatment and an early warning of its 
recurrence time is crucial. The early warning 
provides a basis for the decision of whether to 
continue the same medicine or change to another 
medicine. The medical community relies heavily 
on an answer to the question: what do the data 
suggest? The statistical community is obligated 
to devise an appropriate statistical methodology 
to analyze a patient’s data to make a 
probabilistic early warning regarding whether a 
time period of length τ will be tumor recurrence 
free. 
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The current literature does not contain 
information to answer these questions. To 
compensate for the gaps in this area, this study 
was undertaken to introduce a new statistical 
methodology to fulfill the need for making an 
early probabilistic warning of tumor recurrence 
during a tumor free period of length τ. 
Let T > 0 represent a random time in 
which a tumor (malignant or benign) reoccurs in 
a patient. Given the collected data on his/her 
recurrence times, could a future period of length 
τ be tumor recurrence free? Suppose that the 
uncertainty in T is governed by non-observable 
incidence parameters θ < β, where θ and β 
portray the tumor recurrence rate and its 
restriction level respectively. A restriction on the 
incidence rate exists due to the effect of the 
given medication. Let ν > 0 be the threshold 
time parameter connecting T, θ and β. To 
capture their intricacies, consider the probability 
density function: 
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for T > ν > 0 in terms of θ and β. The expected 
and variance time of the probability pattern in 
(1) are, respectively, 
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A recurrence is missed if the 
observation period is too short; a longer 
observation period increases the chance of 
recording another tumor recurrence. This 
concept is length biased sampling (see Zelen & 
Feinlieb, 1969 for details on length bias 
phenomenon). The length bias alters the 
statistical assessment of the recurrence trend. A 
caution is necessary regarding how the length-
biased data are analyzed and interpreted. When 
the equal random sampling is replaced by 
proportional length biased sampling, the length-
biased version of the model in (1) is appropriate 
for the recurrent tumor times as follows: 
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where argt etedtumorμ  denotes the actual average tumor 
recurrence time. The probability density 
functions in (1) and (4) are interrelated and their 
relations are used to forecast tumor recurrence in 
this study by employing a methodology to 
analyze tumor recurrence data when its rate is 
restricted due to medication. Using the analytic 
results, an early warning of the next tumor 
recurrence free period of length τ is made. 
Various pertinent information in the length-
biased data are extracted and compared to their 
counterparts under non-biased data. 
 
Results 
To identify whether a tumor recurrence free 
period of length τ exists at the earliest time 
possible, understanding its patterns is 
prerequisite. Since the last major tumor 
recurrence, the probability that a next recurrence 
will happen within a selected time τ > 0 is 
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The actual chance for tumor recurrence 
occurs within τ  units of time and requires an 
adjustment of the captured chance for tumor 
recurrence time. This is revealed in the 
relationship shown in (5); the adjustment is 
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In an instantaneous time (that is,τ ν→ ), no 
adjustment is necessary, but after some time has 
elapsed, a finite amount of adjustment is 
necessary. Both a location shift and a scale 
change are warranted. The location and scale 
shifts are 
( 1)( )β τ ν
θ φ
−
−  
and 
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respectively. 
The captured survival chance without a 
tumor recurrence, that is 
 
( ) Pr [ ]capturedtumor capturedS tτ τ= > )  
 
with the length-biased data is 
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times the actual survival chance, which is 
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in a non-length biased data collection scenario 
without a tumor recurrence before that selected 
timeτ . That is, 
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The cofactor 
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is the impact amount due to sampling bias. The 
captured survivability chance without a tumor 
recurrence before that selected time τ  is an 
over-estimate. The mean and variance time of 
the captured tumor recurrence patterns are 
expressed in terms of the actual average time 
int endedμ  between two tumor recurrences. They 
are 
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if int2 endedtumorφ μ> .                     (8) 
 
Expression (7) suggests a relation 
between the actual average tumor recurrence 
time int endedtumorμ  and the captured average tumor 
recurrence time capturedtumorμ . Equivalently, 
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The actual average tumor recurrence time is not 
linear with the captured recurrence time. 
Interestingly, according to expression (8), the 
captured variance of the recurrence times widens 
if the actual average tumor recurrence time is 
greater. Equivalently, 
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meaning that the actual tumor occurrence time 
variance increases proportionally with the 
captured variance. 
Based on this, the incidence parameters 
of the tumor recurrence probability pattern in (4) 
are estimable with (1) 1 2min( , ,... )nt t t t= , 
2,captured
tumors  and (1)
captured
tumort t−  denoting the 
captured threshold recurrence time, sample 
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variance and mean of the tumor recurrence times 
respectively. The moment estimates are 
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Thus, with estimates for (9), (10) and 
(11), the survival probability in (6) is estimable. 
When ˆ1 ( )capturedtumorS τ−  is significantly large, it 
suggests that early warning is necessary to 
speculate whether the tumor recurrence is likely 
to happen within the selected time τ. In addition, 
the factor 
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signifies the restriction level on tumor 
recurrence due to medication. 
Often the likelihood of noticing a quick 
tumor recurrence if it occurs repeatedly is of 
interest. This can be accomplished using the 
order statistics concept (see David, 2005 for 
details regarding order statistics definitions and 
tools). Suppose that tumor reoccurrence takes 
place n times for a patient and let the order 
statistics be 
 
(1) (2) ( )... nT T Tν ≤ < < < < ∞ ; 
 
then 
arg
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t eted nT Fτ τ> = −  
describes the chance of surviving a period of 
length τ without a tumor recurrence. 
Interestingly, it is observed that 
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The factor 
( 2)
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βφ ν
θ
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θ
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,             (14) 
β 
in (13) with a single incidence (that is, n = 1), 
signifies the over-estimated proportion of the 
chance of having a minimal safe period τ . This 
proportion of over-estimate diminishes as the 
patient experiences more recurrences (that is, as 
n increases). 
 
Examples 
To illustrate results, tumor data from 
Andrews and Herzberg (1990) were selected, 
these data show placebo, pyridoxine drug and 
thiotepa drug groups. The mean and variance of 
tumor recurrence times are calculated for each 
patient along with the captured survivability for 
each patient using (5) and the cofactor using (6). 
(See Tables 1A, 2A and 3A.) For example, the 
patient with ID# 13 in the placebo group has 
0.71 captured chance of survivability without 
tumor recurrence in 12 months and the actual 
survivability chance is 0.03 times the captured 
chance of surviving without tumor recurrence. 
Using expressions (9) through (11), the 
incidence parameters are estimated and are 
displayed in Tables 1B, 2B and 3B. For 
example, the parameter estimates φˆ ,   
νˆ  and the restriction gap (.) in 
(.)θ β<  on the incidence rate for patient #13 in 
the placebo group are 0.53, 2.14 and 3 
respectively; patient #15 is an anomaly. Results 
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presented in in Tables 1B, 2B and 3B also show 
the chance of a patient having a safe period 
without any tumor recurrence for the next twelve 
months is calculated using (13), and estimates 
for how much the over-estimation might have 
been in the length biased data are calculated 
using (14). 
The restriction level in (12), location 
shift 
 
( 1)( )β τ ν
θ φ
−
−  
 
and scale shift 
 
1 ( 1)( )β τ ν
θ φ
−
+ −  
 
due to length-biased sampling are calculated and 
displayed in Tables 1 B through 3 B. For 
example, patient #13 had 4.58, 19.2 and 20.2 as 
his/her restriction level for the incidence 
parameters, location and scale shifts due to 
length-biased sampling. Patient # 13 is in the 
placebo group and has 0.03 chance of having a 
safe next twelve months without any tumor 
recurrence. If the length biased captured data are 
used for this patient, the chance of having safe 
next twelve months without any tumor 
recurrence would have been over estimated by 
an amount 0.09. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 1, 2 and 3 illustrate the pattern 
of actual survival chance in terms of the data 
captured for placebo, pyridoxine drug and 
thiotepa drug groups. Note that one outlier case 
(patient #15) is present in the placebo group. In 
addition, it is notable that the trend for the 
pyridoxine group is a reversed direction 
compared to the other two groups; patients in the 
pyridoxine drug group display an upward curve 
while the placebo group and the thiotepa drug 
group have downward curves. 
 
Conclusion 
If other predictor variables are available, a 
logistic regression can be built for patients. In 
addition, the more and less important predictors 
can be identified based on the estimate of 
survivability without a tumor recurrence in the 
next 12 months. 
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Table 1A: Recurrence Times (in Months) of Tumor Placebo Patients 
ID 1st 2nd 3rd 4th 5th 6th 7th 8th 9th (1)t t  2ts  
Captured Survivability 
in 12 Months Cofactor
13 3 13 7       3 7.7 25 0.71 0.03 
15 7 3 6 8      3 6 4.67 0.03 0.15 
16 3 12 10       3 8.33 22.3 0.65 0.05 
24 28 2        2 15 338 0.98 0.003 
34 16 3 4 5 6 5 6   3 6.42 18.95 0.66 0.04 
44 3 12 31 5 2     3 10.6 145.3 0.96 0.005 
48 2 6 4 1 4 4 12 16 15 1 7,2 34.44 0.81 0.02 
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Table 1B: Parameter Estimates of Tumor Placebo Patients 
ID φˆ  (.)θ β<  νˆ  Restriction Level 
Location 
Shift 
Scale 
Shift 
Actual 
Chance of 
Safe 12 
Months 
Overestimated 
Proportion in the Chance 
of Safe 12 Months in the 
Length Biased Data 
13 0.53 (2.140 3 4.58 19.2 20.2 0.03 0.09 
15 84.46 (39.38) 3 3.02 4.09 5.09 0.02 0.95 
16 0.84 (2.23) 3 3.46 13.11 14.11 0.04 0.14 
24 0.03 (2.00) 2 Infinity 270.69 271.69 0.003 0.004 
34 0.58 (2.18) 3 8.73 18.16 19.16 0.03 0.11 
44 0.06 (2.00) 3 85.69 154.9 155.9 0.006 0.008 
48 0.29 (2.07) 1 3.64 40.3 41.35 0.02 0.03 
 
Table 2A: Recurrence Times (in Months) of Tumor Patients Treated with Pyridoxine Drug 
ID 1st 2nd 3rd 4th 5th 6th 7th 8th 9th (1)t t  2ts  
Captured Survivability in 12 
Months Cofactor
51 3 1        1 2 2 0.007 0.06 
64 3 7 12 4 8     3 6.8 12.7 0.46 0.07 
67 3 4 5 4 3 9 6 2 3 2 4.33 4.5 0.08 0.10 
70 2 4 4 6 7 4 9 3 3 2 4,67 5 0.10 0.10 
 
Table 2B: Parameter Estimates of Tumor Patients Treated with Pyridoxine Drug 
ID φˆ  (.)θ β<  (1)t  Restriction Level 
Location 
Shift 
Scale 
Shift 
Actual Chance 
of Safe 12 
Months 
Overestimated Proportion 
in the Chance of Safe 12 
Months in the Length 
Biased Data 
51 6 8 1 Infinity 12.83 13.83 0.0006 0.52 
64 1.52 2.52 3 3.67 9.03 10.03 0.05 0.25 
67 5.87 5.27 2 3.55 7.29 8.29 0.01 0.55 
70 5.38 4.81 2 3.31 7.08 8.08 0.01 0.52 
 
Table 3A: Recurrence Times (in Months) of Tumor Patients Treated with Thiotepa Drug 
ID 1st 2nd 3rd 4th (1)t  t  2ts  
Captured Survivability in 
12 Months Cofactor 
89 18 0   0 13.3 40.5 0.97 0.003 
104 24 2 3 11 2 10 103.3 0.94 0.007 
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Table 3B: Parameter Estimates of Tumor Patients Treated with Thiotepa Drug 
ID φˆ  (.)θ β<  (1)t Restriction Level 
Location 
Shift 
Scale 
Shift 
Actual Chance 
of Safe 12 
Months 
Overestimated 
Proportion in the Chance 
of Safe 12 Months in the 
Length Biased Data 
89 0.04 2.00 0 infinity 288 289 0.003 0.003 
104 0.09 2.01 2 8.78 105.5 106.5 0.008 0.01 
 
Figure 1: Actual Survival Chance in Terms of Captured Survival Chance for Placebo Group 
 
 
 
Figure 2: Actual Survival Chance in Terms of Captured Survival Chance for Pyridoxine Drug Group 
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Figure 3: Actual Survival Chance in Terms of Captured Survival Chance for Thiotepa Drug Group 
 
 
